Opus Genetics is trading 5.11% up now at $3.81, with the move appearing consistent with speculative positioning ahead of anticipated three-month OPGx-BEST1 Cohort 1 topline data expected during the second week of September 2026.
- The stock is rising despite broader biotechnology and equity-market weakness.
- No new company-specific announcement was identified on September 1, 2026, leaving the catalyst unconfirmed.